Skip to main content

Table 1 Demographic and clinical characteristics of patient between groups

From: Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study

Variable

IDS + HIPEC (n = 121)

IDS alone (n = 76)

p-value

Demographic mean (SD)

 Age

58.38 (10.89)

55.20 (10.87)

0.337ª

 BMI (kg/m2) (SD)

26.77 (2.78)

26.65 (2.40)

0.277ª

Neo-adjuvant chemotherapy cycles, n (%)

  

0.442b

 Two cycles

28 (23.1)

20 (26.3)

 

 Three cycles

74 (61.2)

47 (61.8)

 

 Four cycles

19 (15.7)

9 (11.8)

 

Cyto-reductive surgery, n (%)

  

0.734b

 Optimal (R0 + R1)

113 (93.4)

70 (92.1)

 

 Sub-optimal (residual disease > 1 cm)

8 (6.6)

6 (7.9)

 

Bowel resection, n (%)

  

0.523b

 No bowel resection performed

101 (83.5)

66 (86.8)

 

 Bowel resection performed

20 (16.5)

10 (13.2)

 

Mean duration of hospitalization-days (SD) after surgery

8.91 (1.89)

8.07 (1.80)

0.001a

Median time to postoperative systemic treatment with chemotherapy (SD)

22 (2.37)

15 (1.87)

0.001a

Performance status (ECOG), n (%)

  

0.980b

 0

38 (31.4)

24 (31.6)

 

 1

83 (68.6)

52 (68.4)

 

TC chemotherapy cycles after IDS (%)

  

0.015b

 3 cycles

6 (5.0)

5 (6.6)

 

 4 cycles

58 (47.9)

49 (64.5)

 

 5 cycles

57 (47.1)

22 (28.9)

 

Total of TC cycles (SD)

6.73 (0.53)

6.48 (0.66)

0.047b

  1. aAnalysed using an Independent-Samples t-test; bAnalysed using the Mann-Whitney U test. ECOG: Eastern collaborative oncology group. TC: Paclitaxel and carboplatin